COMMUNIQUÉS West-GlobeNewswire

-
Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis
17/10/2025 -
Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population
17/10/2025 -
Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia
17/10/2025 -
IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences
17/10/2025 -
Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01
17/10/2025 -
Vystar’s Vytex® Cloud Bed-in-a-Box Available for Sale
17/10/2025 -
CDT Equity Increases Bitcoin Holding
17/10/2025 -
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17/10/2025 -
BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways
17/10/2025 -
24/7 Market News- Kraig Labs Spider Silk Poised to Lead the Sustainable Textile Revolution
17/10/2025 -
Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week
17/10/2025 -
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
17/10/2025 -
WeightWatchers Launches RxFlexFund™, a New Employer Model for Expanding GLP-1 Coverage
17/10/2025 -
Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
17/10/2025 -
Protext Mobility, Inc. (OTC: TXTM) Announces Plans for Corporate Website Redesign and Investor Relations Suite to Enhance Transparency and Shareholder Engagement
17/10/2025 -
Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025
17/10/2025 -
ITM to Announce Phase 3 COMPETE Trial Post Hoc Subgroup Analyses and Host Satellite Symposium at NANETS 2025
17/10/2025 -
AKYNZEO® demonstrates superior prevention of chemotherapy-induced nausea and vomiting compared to the standard of care in patients receiving moderately emetogenic chemotherapy with additional predictive factors
17/10/2025 -
TOLREMO therapeutics Completes First In Human Dose Escalation for TT125-802 and Presents Solid Tumor Monotherapy Results at ESMO 2025
17/10/2025
Pages